Posts

French vaccine developer Valneva on Thursday cut its full-year revenue outlook citing lower demand for its anti-COVID shot from European Union member states.

Bavarian Nordic raised the company’s financial guidance for 2022 for the third time in a month on Friday after receiving a large order for its monkeypox vaccine by the U.S. Biomedical Advanced Research and Development Authority (BARDA).